Table 1.
Clinical trials of immunotherapy for ovarian cancer.
| Immunotherapy treatment strategy | Not yet recruiting | Recruiting | Active, not recruiting |
|---|---|---|---|
| Autologous dendritic cell vaccination | NCT03905902 | ||
| Autologous dendritic cell vaccination + chemotherapy | NCT03657966 | ||
| Autologous monocytes + peginterferon + interferon | NCT02948426 | ||
| Autologous T cells therapy | NCT02346747 | ||
| NCT01309230 | |||
| Autologous T cells therapy + CD274 antibody | NCT02725489 | ||
| Autologous T cells therapy + PD-L1 inhibitor | NCT03073525 | ||
| cancer vaccine (V3-OVA) | NCT03556566 | ||
| CAR-T | NCT03638206 | ||
| CD274 antibody + chemotherapy | NCT02431559 | ||
| CTLA-4 inhibitor + PARPi | NCT04034927 | ||
| NCT02571725 | |||
| CTLA-4 inhibitor + CD274 antibody + chemotherapy | NCT03249142 | ||
| NCT03277482 | |||
| HER-2/neu peptide vaccine | NCT00194714 | ||
| Oncolytic vaccinia virus + chemotherapy + VEGF-A | NCT02759588 | ||
| PD1 inhibitor | NCT03755739 | ||
| NCT03959761 | |||
| PD1 inhibitor + chemotherapy | NCT02608684 | ||
| NCT03914612 | |||
| NCT03914612 | |||
| NCT03989336 | |||
| NCT03539328 | |||
| PD1 inhibitor + PARPi | NCT03824704 | ||
| PD1 inhibitor + TLR-3 agonist +chemotherapy | NCT03734692 | ||
| PD1 inhibitor + CA125 antibody | NCT03100006 | ||
| PD1 + cancer vaccine | NCT03761914 | ||
| PD1+ cancer vaccine + chemotherapy | NCT03836352 | ||
| PD-L1 inhibitor + CD137 antibody | NCT02554812 | ||
| TCR | NCT03412877 | ||
| TIL | NCT01174121 | ||
| TLR-3 agonist + CA125 antibody | NCT03162562 |
PD-L1, programmed death-ligand 1; CAR-T, chimeric antigen receptor T cells; CTLA-4, cytotoxic T lymphocyte–associated protein 4; PARPi, poly ADP ribose polymerase inhibitors; PD1, programmed cell death protein 1; HER-2, human epidermal growth factor receptor 2; TLR-3, Toll-like receptor 3; VEGF-A, vascular endothelial growth factor A; TCR, T cell receptor; TIL, tumor-infiltrating lymphocytes.